Interested in this peptide?
Request more information and our team will get back to you within 2 business days.
What Is LL-37?
LL-37 is a 37-amino acid antimicrobial peptide (AMP) that represents the only cathelicidin found in humans. Its name derives from its two N-terminal leucine residues (LL) and its length (37 amino acids). It's produced by cleavage of the precursor protein hCAP18 (human cationic antimicrobial protein 18).
LL-37 is produced by epithelial cells, neutrophils, monocytes, and other immune cells. It's found throughout the body at barrier surfaces including skin, respiratory tract, and gastrointestinal tract.
Key Characteristics
- Structure: Alpha-helical conformation in membrane environments
- Expression: Constitutive and inducible (by infection, vitamin D)
- Uniqueness: Only human cathelicidin
- Multifunctional: Antimicrobial + immune modulation
Mechanism of Action
Antimicrobial Activity
LL-37 kills pathogens through several mechanisms:
- Membrane Disruption: Cationic charge binds to negatively charged bacterial membranes
- Pore Formation: Creates holes in pathogen cell membranes
- Biofilm Disruption: Breaks down protective biofilm structures
- Broad Spectrum: Active against bacteria, fungi, viruses, and parasites
Immunomodulatory Functions
Beyond direct killing, LL-37 modulates immune responses:
- Chemotaxis — attracts immune cells to infection sites
- Modulates cytokine production
- Neutralizes lipopolysaccharide (LPS) — reducing septic inflammation
- Promotes wound healing and angiogenesis
- Activates various cell surface receptors
Receptor Interactions
LL-37 interacts with multiple cell receptors:
- FPRL1/FPR2: Formyl peptide receptor — chemotaxis
- P2X7: Purinergic receptor — inflammation
- EGFR: Epidermal growth factor receptor — wound healing
- TLRs: Toll-like receptors — immune activation
Research Areas
Infectious Disease
Extensive research on antimicrobial applications:
- Bacterial Infections: Activity against S. aureus, E. coli, P. aeruginosa, MRSA
- Biofilm-Associated Infections: Disruption of bacterial biofilms
- Viral Infections: Studies on influenza, HSV, HIV, respiratory viruses
- Fungal Infections: Activity against Candida species
Wound Healing
Significant research in tissue repair:
- Enhanced keratinocyte migration
- Promoted angiogenesis in wound beds
- Modulation of inflammation during healing
- Re-epithelialization effects
Inflammatory Conditions
Research in various inflammatory states:
- Psoriasis — LL-37 is elevated and may contribute to pathology
- Rosacea — similar involvement in disease process
- Atherosclerosis — complex pro/anti-inflammatory roles
- Arthritis models — mixed research findings
Cancer Research
Emerging research on anticancer properties:
- Direct cytotoxicity against some cancer cell lines
- Immune activation against tumors
- Anti-angiogenic effects in tumor contexts
- Potential synergy with conventional therapies
Vitamin D Connection
LL-37 and Vitamin D
- Vitamin D strongly induces LL-37 expression
- The LL-37 gene (CAMP) has vitamin D response elements
- This may explain some immune benefits of vitamin D
- Deficiency in vitamin D correlates with reduced LL-37 levels
Key Published Studies
| Year | Focus Area | Key Finding | Reference |
|---|---|---|---|
| 2001 | Wound healing | Promoted re-epithelialization | Heilborn et al. |
| 2006 | Vitamin D link | Defined vitamin D-LL37 pathway | Liu et al., Science |
| 2008 | Biofilms | Demonstrated biofilm disruption | Overhage et al. |
| 2014 | Antiviral | Activity against influenza virus | Tripathi et al. |
| 2019 | Cancer | Antitumor mechanisms described | Chen et al. |
Therapeutic Development
Challenges and approaches in developing LL-37-based therapies:
Challenges
- Susceptibility to proteolytic degradation
- High cost of synthesis (37 amino acids)
- Potential toxicity at high concentrations
- Activity reduced by physiological salt concentrations
Research Approaches
- Shortened analogs (e.g., IG-19, KR-12)
- Modified sequences for stability
- Topical formulations for wound care
- Combination with conventional antibiotics
Research Status
LL-37 and its analogs remain research compounds. While the natural peptide plays important roles in human immunity, therapeutic applications are still under investigation. Some analogs have entered clinical trials for specific indications, but none are currently approved for general therapeutic use.
Summary
LL-37 exemplifies the dual role of antimicrobial peptides — combining direct pathogen killing with sophisticated immune modulation. As the only human cathelicidin, it's a critical component of innate immunity found at all body surfaces. Research continues to explore therapeutic applications, particularly for antibiotic-resistant infections and wound healing, while addressing challenges of stability and delivery.